MMED

David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depth NORTHRIDGE, Calif., June 29, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that David Endicott and Linnea Burman have joined its Board of Directors, effective today, expanding the Board from nine to 11 members.

MMED expands its European diabetes tech reach with Abbott sensor integration, boosting user flexibility and its connected care ecosystem.

MiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company's portfolio NORTHRIDGE, Calif., June 23, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the commercial launch in Europe of both the MiniMed™ 780G system integrated with the Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor.

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor NORTHRIDGE, Calif., June 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), today announced its first commercial launch of the MiniMed Flex™ system in the United States — its first app-controlled pump and the company's smallest insulin pump yet.

MiniMed Group NASDAQ: MMED reported record fiscal 2026 revenue and outlined a slate of product launches it said will support faster growth in fiscal 2027, as management held the company's first earnings call as a standalone public company following its March IPO.

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.

Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic Advanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDI NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026.

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data NORTHRIDGE, Calif., May 27, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced an overview of its upcoming presence at the American Diabetes Association's (ADA) Scientific Sessions in New Orleans June 5-8.

NORTHRIDGE, Calif., May 26, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in a fireside chat at the upcoming Goldman Sachs 47th Annual Global Healthcare Conference.

MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.